Figure 3From: The cost effectiveness of teriparatide as a first-line treatment for glucocorticoid-induced and postmenopausal osteoporosis patients in Sweden Scatter Plot of Incremental Costs and QALYs for PMO T −3.0/2 Fracture Cohort: Teriparatide vs. Bisphosphonate Treatment. Back to article page